Clinical Trials Browser

Phase 1/2 × OTHER × selinexor × Clear all

NCT06239272 2026-04-21

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT07479979 2026-03-23

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT03147885 2025-09-29

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06449482 2025-05-30

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Phase 1/2 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02178436 2023-11-07

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Phase 1/2 Completed

15 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04138381 2023-03-27

SeliGIST

Phase 1/2 Unknown

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02780609 2022-11-04

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase 1/2 Completed

22 enrolled 16 charts

Multiple Myeloma

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

NCT04891744 2021-05-18

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Phase 1/2 Unknown

Multiple Myeloma

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Phase 1/2 Completed

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02416908 2020-03-13

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

40 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02536495 2015-10-30

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Phase 1/2 Withdrawn

Recurrent Squamous Cell Lung Carcinoma